| HOME >> BIOLOGY >> TECHNOLOGY |
DUBLIN, Ohio, July 31 /PRNewswire-FirstCall/ -- Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, today announced a three-year agreement with Prime Therapeutics, one of the nation's leading pharmacy benefit managers, to serve as its primary supply chain partner for branded and generic pharmaceuticals, effective August 1.
Prime Therapeutics managed more than $8.2 billion in prescription drug spend in 2007, and currently serves approximately 14.6 million members through Blue Cross and Blue Shield Plans, employer and union groups and third-party administrators.
"We look forward to delivering the pharmaceutical supply chain services that will help Prime Therapeutics continue to efficiently and effectively serve its patients' medication needs," said Mike Kaufmann, group president of Healthcare Supply Chain Services - Pharmaceutical for Cardinal Health. "This agreement is an excellent example of our commitment to building flexible, mutually beneficial partnerships with our customers that also enable us to grow our pharmaceutical distribution business."
Cardinal Health will also offer Prime Therapeutics additional supply chain optimization services to help improve its operational efficiency.
"This innovative new partnership will provide us with the benefits of buying through a drug wholesaler and the insights and expertise of direct generics buying," said Tim Dickman, Prime Therapeutics CEO. "Cardinal Health was selected as our primary distributor because they offer the experience, value-added services and flexibility that we need to continue to deliver quality, cost-efficient prescription drug benefits to our customers."
About Prime Therapeutics
Prime Therapeutics is a pharmacy benefit management company dedicated
to providing innovative, clinically based, cost-effective pharmacy
solutions for clients and members. Providing pharmacy benefit services
nationwi
'/>"/>
| SOURCE Cardinal Health, Inc. Copyright©2008 PR Newswire. All rights reserved |